Alert detail
FDA Approval: OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW) — Type 1 - New Molecular Entity
Policy ID: FDA-BLA761234Specialty: OncologyAdded: 6/13/2026Effective: 2022-03-18billing update
Full alert analysis requires a subscription
Subscribe to access the complete alert summary, AI-generated action recommendations, source document links, LCD revision comparisons, and related alerts.